Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

NCT05855200 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

892

Enrollment

INDUSTRY

Sponsor class

Conditions

Colonic Neoplasms
Neoplasms, Colon

Interventions

BIOLOGICAL: Dostarlimab
DRUG: CAPEOX
DRUG: FOLFOX

Sponsor

GlaxoSmithKline